177lu-dota-cg250
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2005 (NCT00142415)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Carbonic anhydrase IXImmunity, passive
CA9 immunity, passive
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 177-Lutetium
Oral
No
Parenteral
No
Topical
No
Also known as
- 177lu-dota-cg250
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00142415 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2005 | Ludwig Institute for Cancer Research, Radboud University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 1 | 1 | 2005 |
| Radboud University | Academic/Hospital | 1 | 0 | 1 | 2005 |
2 organizations
Page 1 / 1